Resverlogix Conference Call & Webcast to Announce Platform Mechanism of Action

CALGARY, Alberta, Canada, Apr. 19, 2012 /CNW-AsiaNet/ –

Dr. Stephen J. Nicholls joins as guest speaker

TSX Exchange Symbol: RVX

Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) is pleased to announce for the first time the “Mechanism of Action” (MoA) by which RVX-208 increases apolipoprotein A-I (ApoA-I) production. Please join us via Conference Call & Webcast on Monday, April 23, 2012, commencing at 11 am EDT. Dr. Stephen J. Nicholls, Heart Disease Theme Leader at the South Australian Health and Medical Research Institute, will join Resverlogix’ President and Chief Executive Officer Donald McCaffrey and Chief Scientific Officer Dr. Norman Wong for an in-depth presentation.

Link to access the Webcast:

Conference call dial-in numbers:
Canada & USA Toll Free Dial In: 1-800-319-4610
Outside of Canada & USA call: +1-604-638-5340

In other news, Resverlogix is pleased to announce two important presentations. Donald McCaffrey will be presenting on Friday, April 20, 2012 at BioCentury Future Leaders in the Biotech Industry in New York, NY. On April 21, 2012, Drs. Norman Wong and Peter Young will be presenting at the ATVB HDL Workshop Meeting in Chicago, IL.

About RVX-208

RVX-208 is a novel small molecule that stimulates endogenous ApoA-I production to trigger the synthesis of HDL. The use of this approach will enhance the functionality of HDL. ApoA-I is the major protein component of HDL. The main role of these particles is to act as the body’s natural defense system against atherosclerosis by mediating a normal physiologic process called reverse cholesterol transport (RCT). This pathway enables cholesterol, including that within atherosclerotic plaques of vessel walls, to be transported to the liver for further processing and elimination from the body. Enhanced RCT clearance of cholesterol from vessel walls is expected to reduce or prevent atherosclerosis. The ability of RVX-208 to increase ApoA-I production and thereby augment RCT differentiates it from other HDL therapies. RVX-208 is positioned to be one of the most promising drugs in development for the treatment of atherosclerosis.

Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ technology platform is the Company’s primary focus, developing novel small molecules that enhance ApoA-I production. These vital therapies are focused on addressing the burden of Atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer’s disease, Peripheral Artery Disease, Oncology and Autoimmune diseases. Resverlogix Corp.’s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company’s products, the availability of government and insurance reimbursements for the Company’s products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Resverlogix Corp.

Company Contacts:

Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: +1-403-254-9252

Sarah Zapotichny
Director of Investor Relations
Resverlogix Corp.
Phone: +1-403-254-9252

US Institutional Investors:

Susan Noonan
Managing Partner
S.A. Noonan Communications, LLC
Phone: +1-212-966-3650